Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133356 | 0.88 | KDM4E (0.51) | KDM4EHTTTSHRALOX15CASP1 | |
| SCHEMBL6133496 | 0.87 | KDM4E (0.54) | KDM4EHTTTSHRALOX15CASP1 | |
| SCHEMBL6134162 | 0.87 | MEN1 (0.51) | KDM4ETSHRALOX15CASP1ALDH1A1 | |
| SCHEMBL6134080 | 0.86 | KDM4E (0.53) | KDM4EHTTTSHRALOX15CASP1 | |
| SCHEMBL6134015 | 0.85 | KDM4E (0.45) | KDM4EHTTTSHRALDH1A1MEN1 | |
| SCHEMBL6133255 | 0.85 | HTT (0.47) | KDM4EHTTTSHRALDH1A1MEN1 | |
| SCHEMBL6920286 | 0.84 | HTT (0.43) | KDM4EHTTTSHRALDH1A1MEN1 | |
| SCHEMBL6133470 | 0.83 | ALDH1A1 (0.47) | KDM4EHTTTSHRALOX15CASP1 | |
| SCHEMBL6133701 | 0.83 | KDM4E (0.46) | KDM4EHTTTSHRALOX15ALDH1A1 | |
| SCHEMBL6133813 | 0.82 | ALOX15 (0.46) | KDM4EHTTTSHRALOX15CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1441732-A2 | THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003039451-A2 | THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004134-A1 | Thiazole derivative and pharmaceutical use thereof | MC2R, CYP2C9, OXTR | KDM4E 3814/4885HTT 477/4885TSHR 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.